Goldman Sachs Group Inc Cel Sci Corp Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$1.99 - $3.52 $10,513 - $18,596	-5,283 Reduced 30.86%	11,836 $27,000
Q4 2022 Feb 13, 2023	SELL	$1.99 - $3.52 $10,513 - $18,596	-5,283 Reduced 30.86%	11,836 $27,000
Q3 2022 May 14, 2024	SELL	$3.09 - $5.23 $44,115 - $74,668	-14,277 Reduced 45.47%	17,119 $53,000
Q3 2022 Nov 10, 2022	SELL	$3.09 - $5.23 $44,115 - $74,668	-14,277 Reduced 45.47%	17,119 $0
Q2 2022 May 14, 2024	BUY	$2.58 - $4.99 $81,001 - $156,666	31,396 New	31,396 $141,000
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $805,119 - $1.56 Million	-312,062 Reduced 90.86%	31,396 $141,000
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $1.08 Million - $2.12 Million	274,854 Added 400.64%	343,458 $1.35 Million
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $107,991 - $194,992	15,210 Added 28.49%	68,604 $487,000
Q3 2021 Nov 10, 2021	BUY	$7.64 - $12.49 $407,930 - $666,891	53,394 New	53,394 $587,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.